GMED 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-05-07

• The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and related notes that appear in Item 1 of this Quarterly Report on Form 10-Q and with our audited consolidated fina…

• In the U.S., net sales increased by $121.0 million, or 25.0%, for the three months ended March 31, 2026. From a product standpoint, the increase was primarily driven by Nevro sales of $67.2 million and increased Musculoskeletal Solutions sales of $53.7 million, which such sales were driven by increa…

• The $38.7 million, or 19.8%, increase in cost of sales for the three months ended March 31, 2026 was primarily driven by the cost of sales from Nevro products of $26.2 million, an increase in product cost of $4.0 million driven primarily by higher volume, and an increase in freight cost of $4.0 mill…

• The $3.4 million, or 10.4%, increase in research and development expenses was primarily driven by an increase of $3.9 million for Nevro research and development expenses.

• The increase of $55.0 million, or 22.6%, in selling, general and administrative expenses was primarily driven by an increase of $46.1 million for Nevro expenses. The remaining increases include an increase of $8.1 million in employee-related expenses, an increase of $3.3 million in outside consultin…

相对上期删除的文字 · 来源:10-Q · 2025-11-06

• The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and related notes that appear in Item 1 of this Quarterly Report on Form 10-Q and with our audited consolidated fina…

• In the United States, the increase in net sales was $121.8 million, or 24.6%, for the three month period ended September 30, 2025. From a product standpoint, net sales increased by $131.7 million, primarily driven by Nevro sales of $83.3 million, and Musculoskeletal Solutions and Neuromonitoring sal…

• The increase in Musculoskeletal Solutions net sales was partially offset by a decrease in Enabling Technology sales of $0.3 million, primarily driven by lower unit placement.

• The $18.0 million or 6.6% decrease in cost of sales was driven primarily by decreased amortization of inventory fair value step-up which contributed $6.9 million from Nevro acquired inventory in the current year as compared to $60.8 million from NuVasive acquired inventory in the prior year. This de…

• The $2.7 million or 7.6% increase in research and development expenses was primarily driven by an increase of $4.2 million for Nevro expenses and an increase of $1.6 million for supplies, parts used from inventory, and dues and subscriptions. This was partially offset by a decrease of $3.4 million f…

相对上期删除的文字 · 来源:10-Q · 2025-11-06

• Our management has performed its assessment according to the guidelines established by the Committee of Sponsoring Organizations of the Treadway Commission. Management excluded Nevro from its assessment of internal controls over financial reporting, as it was not possible to conduct an assessment of…

相对上期新增的文字 · 来源:10-Q · 2026-05-07

• In addition, we are subject to legal proceedings arising in the ordinary course of business. Consistent with Item 103 of Regulation S-K, we have elected to disclose those environmental proceedings with a governmental entity as a party where the Company reasonably believes that such proceeding would …

相对上期删除的文字 · 来源:10-Q · 2025-11-06

• In addition, we are subject to legal proceedings arising in the ordinary course of business.

相对上期新增的文字 · 来源:10-Q · 2026-05-07

• Except as set forth below, during the quarter ended March 31, 2026, none of our directors or officers (as defined in Rule 16a-1 under the Exchange Act) adopted, modified or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement” (as those terms are defined in Item 408…

• On February 27, 2026, Keith W. Pfeil, the Company’s Chief Executive Officer and President, terminated a trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. Mr. Pfeil’s Rule 10b5-1 trading plan had a term ending upon the earlier of (i) March 15, 2026 or (ii) the …

• On March 13, 2026, Keith W. Pfeil, the Company’s Chief Executive Officer and President, adopted a trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. Mr. Pfeil’s Rule 10b5-1 trading plan has a term ending upon the earlier of (i) June 12, 2027 or (ii) the sale of…

相对上期删除的文字 · 来源:10-Q · 2025-11-06

• On August 12, 2025, Daniel T. Scavilla, former President and Chief Executive Officer, terminated a Rule 10b5-1 Trading Plan. Mr. Scavilla’s Rule 10b5-1 Trading Plan, had a term ending upon the earlier of December 31, 2025 or the sale of all shares subject to the plan. At the time of termination, the…

• On August 25, 2025, Kyle R. Kline, Chief Financial Officer and Senior Vice President, adopted a Rule 10b5-1 Trading Plan. Mr. Kline’s Rule 10b5-1 Trading Plan, which has a term ending upon the earlier of November 30, 2026 or the sale of all shares subject to the plan, provides for the sale of up to …

• On September 12, 2025, Leslie V. Norwalk, Member of the Board of Directors, adopted a Rule 10b5-1 Trading Plan. Ms. Norwalk’s Rule 10b5-1 Trading Plan, which has a term ending upon the earlier of September 11, 2026 or the sale of all shares subject to the plan, provides for the sale of up to 8,000 s…